NEW YORK, May 3 (GenomeWeb News) - Qiagen and Epigenomics have signed a licensing and OEM deal to develop products to analyze DNA methylation, the companies said today.
Under the agreement, Venlo, the Netherlands-based Qiagen exclusively licensed Epigenomics' bisulfite DNA treatment technology as well as its MethyLight assay technology to develop products for research purposes. In exchange, Berlin-based Epigenomics will receive up-front technology access and licensing fees, as well as royalties on the sales of research products.
For diagnostic purposes, Qiagen will market and sell products containing the bisulfite technology for use with Epigenomics' technologies and products. Under an OEM agreement, Qiagen will also provide Epigenomics with kit components for molecular diagnostic products.
All products developed under the agreement will be co-branded, and the first products are expected in 2006.